News archive

More than 100 people from 15 Asian countries participated in the fourth Novartis Social Business stakeholder dialogue in Singapore on November 20.

Volunteerism and giving back to communities where we live and work are more than just tradition; they’re core values.

Leprosy is an ancient disease that currently infects more than 200 000 people each year. For more than three decades, Novartis and the Novartis Foundation has been working to reduce the incidence of leprosy, and the Novartis Foundation recently helped establish the Global Partnership for Zero Leprosy in an effort to eliminate the disease.

Novartis is one of 73 companies included in the 2017 Water A List by CDP, the nonprofit global environmental disclosure platform.

The third Novartis Social Business stakeholder dialogue took place on November 21 in Basel.

RAND Corporation and the Moran Company issued reports discussing the cost savings associated with biosimilars.

The event will take place on November 21 in Basel.

Individualized CAR‑T therapy uses a patient’s own immune system to fight certain types of cancers.

Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR) and Vas Narasimhan, Head of Global Drug Development and Chief Medical Officer, share their outlook for innovation in 2017.

Through a successful patient support program, Novartis is taking diabetes care beyond the pill in India.